Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0G4IW
|
|||
| Drug Name |
CART-19
|
|||
| Drug Type |
CAR T Cell Therapy
|
|||
| Indication | Acute lymphoblastic leukaemia [ICD-11: 2A85; ICD-10: C85.1, C88.7] | Phase 2 | [1], [2] | |
| Chronic lymphocytic leukaemia [ICD-11: 2A82.0; ICD-10: C83.0, C91.1] | Phase 2 | [1], [3] | ||
| Non-hodgkin lymphoma [ICD-11: 2B33.5; ICD-10: C85.9] | Phase 2 | [4] | ||
| B-cell chronic lymphocytic leukaemia [ICD-11: 2A82.00; ICD-9: 204.1] | Phase 1 | [1] | ||
| B-cell lymphoma [ICD-11: 2A86; ICD-10: C85.1; ICD-9: 202.8] | Phase 1 | [5] | ||
| Diffuse large B-cell lymphoma [ICD-11: 2A81; ICD-10: C83.3; ICD-9: 200] | Phase 1 | [1] | ||
| Follicular lymphoma [ICD-11: 2A80; ICD-9: 202] | Phase 1 | [1] | ||
| Haematopoietic/lymphoid cancer [ICD-11: 2B33.5; ICD-10: C85.9] | Phase 1 | [1] | ||
| leukaemia [ICD-11: 2A60-2B33; ICD-9: 208.9] | Phase 1 | [5] | ||
| Mantle cell lymphoma [ICD-11: 2A85.5; ICD-10: C83.1] | Phase 1 | [1] | ||
| Prolymphocytic leukaemia [ICD-11: 2A82.1; ICD-10: C91.3] | Phase 1 | [1] | ||
| Company |
University of Pennsylvania
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | B-lymphocyte surface antigen B4 (CD19) | Target Info | CAR-T-Cell-Therapy | [1], [2], [3], [4], [5] |
| KEGG Pathway | PI3K-Akt signaling pathway | |||
| Hematopoietic cell lineage | ||||
| B cell receptor signaling pathway | ||||
| Epstein-Barr virus infection | ||||
| Primary immunodeficiency | ||||
| NetPath Pathway | IL-7 Signaling Pathway | |||
| Panther Pathway | B cell activation | |||
| Pathway Interaction Database | BCR signaling pathway | |||
| Reactome | PIP3 activates AKT signaling | |||
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | ||||
| Constitutive Signaling by Aberrant PI3K in Cancer | ||||
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | ||||
| WikiPathways | Human Complement System | |||
| Signaling by the B Cell Receptor (BCR) | ||||
| PIP3 activates AKT signaling | ||||
| B Cell Receptor Signaling Pathway | ||||
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01029366) CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy | |||
| REF 2 | ClinicalTrials.gov (NCT02030847) Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or Refractory Acute Lymphoblastic Leukemia | |||
| REF 3 | ClinicalTrials.gov (NCT01747486) CD19 Redirected Autologous T Cells | |||
| REF 4 | ClinicalTrials.gov (NCT02030834) Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas | |||
| REF 5 | ClinicalTrials.gov (NCT01626495) Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.